David Planchard

David Planchard

UNVERIFIED PROFILE

Are you David Planchard?   Register this Author

Register author
David Planchard

David Planchard

Publications by authors named "David Planchard"

Are you David Planchard?   Register this Author

100Publications

3616Reads

29Profile Views

Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.

N Engl J Med 2020 01 21;382(1):41-50. Epub 2019 Nov 21.

From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.S.R.); the Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium (J.V.); the Thoracic Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif (D.P., J.-C.S.), and University Paris Sud, Orsay (J.-C.S.) - both in France; the Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and the Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju (K.H.L.) - both in South Korea; the Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.E.G.); the Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka (F.I.), and the Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka (T.K.) - all in Japan; Pulmonary Hospital of Tongji University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun (Y.C.) - both in China; the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), and the Oncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai (B.C.) - both in Thailand; Kent Oncology Centre, Maidstone Hospital, and Tunbridge Wells NHS Trust, Maidstone (R.S.), and Late Oncology Statistics (A.T., R.H.) and Oncology Research and Development (M.S., Y.R.), AstraZeneca, Cambridge - both in the United Kingdom; Hospital Regional Universitario Málaga, Instituto de Investigación Biomédica de Málaga, Malaga, Spain (M.C.); William Osler Health System, University of Toronto, Toronto (P.C.); the Department of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, Parma, Italy (M.T.); the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan (M.-C.L.); and Early Oncology Research and Development, AstraZeneca, Gaithersburg, MD (J.-C.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1913662DOI Listing
January 2020

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.

Ther Adv Respir Dis 2019 Jan-Dec;13:1753466619885530

Head of Thoracic Oncology Group, Medical Oncology Department, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif 94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1753466619885530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831969PMC
November 2019

Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment.

J Cachexia Sarcopenia Muscle 2019 Aug 1;10(4):782-793. Epub 2019 Apr 1.

GHRMSA, Pneumology Department, French College of General Hospital Respiratory Physicians (CPHG), Hôpital Emile Muller, Mulhouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcsm.12418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711412PMC
August 2019

Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors.

J Thorac Oncol 2019 06 13;14(6):993-1002. Epub 2019 Feb 13.

Service d'Oncologie Médicale, Groupement Hospitalier Centre, Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France; University of Lyon, Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.002DOI Listing
June 2019

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

N Engl J Med 2018 12 25;379(24):2342-2350. Epub 2018 Sep 25.

From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), Florida Cancer Specialists, Fleming Island (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee Oncology, Chattanooga (D.D.), and Sarah Cannon Research Institute, Nashville (D.D., D.R.S.) - both in Tennessee; Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and Spanish National Cancer Research Center (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, Hirakata (T.K.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical Centre, Adelaide, SA (C.S.K.) - all in Australia; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes Klinikum Neukoelln, Berlin (M.W.), and the Lung Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.) - both in Germany; Centre Hospitalier Universitaire de Liège, Liège (M.B.), and University Hospitals KU Leuven, Leuven (J.V.) - both in Belgium; Centre Hospitalier Universitaire de Montpellier and Institut du Cancer de Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-site René Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of Pulmonology, Budapest, Hungary (G.O.); the University of Manchester and the Christie NHS Foundation Trust, Manchester (C.F.-F.), AstraZeneca, Alderley Park (C.W.), and AstraZeneca, Cambridge (M.T.) - all in the United Kingdom; AstraZeneca, Gaithersburg, MD (G.M., P.A.D.); and Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1809697DOI Listing
December 2018

Safety of osimertinib in EGFR-mutated non-small cell lung cancer.

Expert Opin Drug Saf 2018 Dec 5;17(12):1239-1248. Epub 2018 Dec 5.

a Medical Oncology Department , Gustave Roussy , Villejuif , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2018.1549222DOI Listing
December 2018

Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients.

J Thorac Oncol 2018 11 6;13(11):e215-e217. Epub 2018 Jun 6.

Medical Oncology Department, Gustave Roussy, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.05.033DOI Listing
November 2018

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 10 20;36(28):2872-2878. Epub 2018 Aug 20.

Matthew D. Hellmann, Parker Institute for Cancer Immunotherapy; Kathryn C. Arbour, Niamh Long, Hira Rizvi, Andy Ni, W. Victoria Lai, Joshua K. Sabari, Andrew J. Plodkowski, Darragh Halpenny, Jamie E. Chaft, Gregory J. Riely, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Kathryn C. Arbour, W. Victoria Lai, Joshua K. Sabari, Jamie E. Chaft, Gregory J. Riely, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Laura Mezquita, Roberto Ferrara, Lizza E.L. Hendriks, Caroline Caramella, Benjamin Besse, and David Planchard, Gustave Roussy Cancer Center, Villejuif; Edouard Auclin, Hôpital Européen Georges Pompidou; Benjamin Besse, Paris-Sud University, Le Kremlin Bicêtre, Paris, France; Gala Martínez-Bernal, Virgen del Rocío Hospital, Seville, Spain; Lizza E.L. Hendriks, Maastricht University Medical Center, Maastricht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.0006DOI Listing
October 2018

Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.

Am Soc Clin Oncol Educ Book 2017;37:12-17

From the Department of Oncology Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Department of Oncology Medicine, Hospital de la Vall d'Hebron, Barcelona, Spain; Institut National du Cancer, Boulogne-Billancourt, France; University Paris-Sud and Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_100007DOI Listing
September 2018

Have We Really MET a New Target?

Authors:
David Planchard

J Clin Oncol 2018 Sep 25:JCO2018793455. Epub 2018 Sep 25.

David Planchard, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.3455DOI Listing
September 2018

Durvalumab for the treatment of non-small cell lung cancer.

Expert Rev Respir Med 2018 08 9;12(8):627-639. Epub 2018 Jul 9.

a Medical Oncology Department , Gustave Roussy , Villejuif , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2018.1494575DOI Listing
August 2018

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.

Arch Pathol Lab Med 2018 07 12;142(7):796-797. Epub 2018 Apr 12.

From the Department of Medical Oncology, Gustave Roussy, Villejuif, France (Dr Planchard); and the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, (Dr Johnson).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0088-EDDOI Listing
July 2018

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

Cancer Treat Rev 2018 May 24;66:82-94. Epub 2018 Apr 24.

Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.04.006DOI Listing
May 2018

Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:726-739

From the Department of Medicine, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_201331DOI Listing
May 2018

Durvalumab in non-small-cell lung cancer patients: current developments.

Future Oncol 2018 Feb 15;14(3):205-222. Epub 2017 Nov 15.

Medical Oncology Department, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0373DOI Listing
February 2018

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

N Engl J Med 2018 01 18;378(2):113-125. Epub 2017 Nov 18.

From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju (K.H.L.), the Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and the Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.E.G.); the Department of Oncology, University College London Hospitals Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all in the United Kingdom; and Emory University School of Medicine, Winship Cancer Institute, Atlanta (S.S.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713137DOI Listing
January 2018

The role of brigatinib in crizotinib-resistant non-small cell lung cancer.

Cancer Manag Res 2018 18;10:123-130. Epub 2018 Jan 18.

Medical Oncology Department, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S129963DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783011PMC
January 2018

Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.

Support Care Cancer 2017 11 8;25(11):3365-3373. Epub 2017 Jun 8.

Département Ambulatoire, Gustave-Roussy, Université Paris-Saclay, F-94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-017-3755-zDOI Listing
November 2017

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

N Engl J Med 2017 11 8;377(20):1919-1929. Epub 2017 Sep 8.

From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and the Spanish National Cancer Research Center (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709937DOI Listing
November 2017

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

J Clin Oncol 2017 Nov 11;35(31):3591-3600. Epub 2017 Sep 11.

Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.9012DOI Listing
November 2017

AZD3759 for CNS metastases in EGFR-mutant lung cancer.

Authors:
David Planchard

Lancet Respir Med 2017 11 19;5(11):841-842. Epub 2017 Oct 19.

Gustave Roussy, Department of Medical Oncology, 94805 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(17)30395-8DOI Listing
November 2017

Are we reproducible in measurement of NET liver metastasis?

Dig Liver Dis 2017 Oct 28;49(10):1121-1127. Epub 2017 Jun 28.

Department of Nuclear Medicine, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2017.05.015DOI Listing
October 2017

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Lung Cancer 2017 10 29;112:10-15. Epub 2017 Jul 29.

Medical Oncology Department, Gustave Roussy, Villejuif, France; University Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.07.004DOI Listing
October 2017

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Lung Cancer 2017 10 7;112:62-68. Epub 2017 Aug 7.

Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France; University Paris-Sud Kremlin Bicetre/Chatenay-Malabry, Le Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.002DOI Listing
October 2017

Targeting ALK-rearranged non-small-cell lung cancer: an update.

Future Oncol 2017 06 7;13(14):1213-1217. Epub 2017 Jun 7.

Medical Oncology Department, Gustave Roussy, 114 rue Édouard Vaillant, 94805, Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0127DOI Listing
June 2017

Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.

Invest New Drugs 2017 04 12;35(2):247-249. Epub 2016 Nov 12.

Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114, rue Edouard Vaillant, 94800, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0405-0DOI Listing
April 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

J Clin Oncol 2017 Apr 21;35(12):1288-1296. Epub 2017 Feb 21.

James Chih-Hsin Yang and Chia-Chi Lin, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China; Myung-Ju Ahn, Sungkyunkwan University; Dong-Wan Kim, Seoul National University Hospital; Sang-We Kim, Asan Medical Center, Seoul; Joo-Hang Kim, CHA University, Gyeonggi-do, Republic of Korea; Suresh S. Ramalingam, Emory University School of Medicine, Atlanta, GA; Lecia V. Sequist, Massachusetts General Hospital; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; David Planchard, Institut Gustave Roussy, Villejuif, France; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Fiona Blackhall, The Christie Hospital; University of Manchester, Manchester; Helen Mann and Serban Ghiorghiu, AstraZeneca, Cambridge; Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; Daniel Haggstrom, Carolinas Healthcare System, Charlotte, NC; Kiyotaka Yoh, National Cancer Center Hospital East, Kashiwa, Chiba; Tomonori Hirashima, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan; Silvia Novello, University of Turin, Turin, Italy; and Kathryn Gold, University of California San Diego Moores Cancer Center, San Diego, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.3223
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.3223DOI Listing
April 2017

Next-Generation Tyrosine Kinase Inhibitors for Treating -Mutant Lung Cancer beyond First Line.

Front Med (Lausanne) 2016 18;3:76. Epub 2017 Jan 18.

Department Medical Oncology, Gustave Roussy , Villejuif , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2016.00076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241298PMC
January 2017

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.

Ther Adv Respir Dis 2016 12 26;10(6):549-565. Epub 2016 Oct 26.

Medical Oncology Department, Gustave Roussy, 114 rue Édouard Vaillant, 94800 Villejuif, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1753465816670498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933598PMC
December 2016

Reply to N. Singh et al.

Authors:
David Planchard

J Clin Oncol 2016 11 31;34(33):4055-4056. Epub 2016 Oct 31.

David Planchard, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.9349DOI Listing
November 2016

Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase ()-positive non-small cell lung cancer in a phase I/II trial".

J Thorac Dis 2016 Oct;8(10):E1287-E1292

Medical Oncology Department, Gustave Roussy, 114 rue Édouard Vaillant, 94800 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2016.10.57DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107501PMC
October 2016

The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer.

Expert Rev Mol Diagn 2015 13;15(12):1605-29. Epub 2015 Nov 13.

a INSERM, U981 "Identification of Molecular Predictors and new Targets for Cancer Treatment" , F-94805 , VILLEJUIF , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737159.2015.1111139DOI Listing
September 2016

Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.

Future Oncol 2016 Apr 19;12(7):945-61. Epub 2016 Feb 19.

Medical Oncology Department, Gustave Roussy, 114 Rue Édouard Vaillant, 94805 Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.16.15DOI Listing
April 2016

Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib?

Authors:
David Planchard

J Clin Oncol 2016 Apr 14;34(12):1292-4. Epub 2016 Mar 14.

Gustave Roussy, Villejuif, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.3344DOI Listing
April 2016

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

Oncoimmunology 2016 Apr 12;5(4):e1071008. Epub 2015 Aug 12.

Gustave Roussy Cancer Campus, Villejuif, France; Laboratoire d'Immunomonitoring en Oncologie, UMS 3655 CNRS / US 23 INSERM Gustave Roussy Cancer Campus, Villejuif, France; Centre d'Investigation Clinique en Biothérapies (CICBT) 1428, Villejuif, France; Laboratoire de Thérapie Cellulaire, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1071008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839329PMC
April 2016

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.

Curr Opin Oncol 2016 Mar;28(2):122-9

aMedical Oncology DepartmentbLaboratoire d'immunomonitoring en Oncologie UMS 3655 CNRS/US 23 INSERM, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000263DOI Listing
March 2016

Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.

Cancer Biomark 2015 ;15(2):151-6

Thoracic Group, INSERM U981, Gustave Roussy, Villejuif, France Department of Medical Oncology, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-140448DOI Listing
February 2016

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.

Ther Adv Med Oncol 2016 Jan;8(1):32-47

Gustave Roussy - Medical Oncology, 114 rue Édouard Vaillant, Villejuif 94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834015617355DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699265PMC
January 2016

[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].

Ann Pathol 2016 Jan 14;36(1):94-102. Epub 2016 Jan 14.

Département de biopathologie, MESOPATH, centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Université Joseph-Fourier, Inserm U823, institut Albert-Bonniot, Grenoble, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annpat.2015.11.004DOI Listing
January 2016

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.

Future Oncol 2015 Nov 9;11(22):3069-81. Epub 2015 Oct 9.

Gustave Roussy, Medical Oncology Department, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.250DOI Listing
November 2015

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].

Bull Cancer 2015 Sep 30;102(9):749-57. Epub 2015 Jul 30.

Institut Gustave-Roussy, département d'innovation thérapeutique et d'essais précoces, 94800 Villejuif, France; Institut Gustave-Roussy, département de médecine oncologique, 94800 Villejuif, France; Université Paris-Sud, 91400 Orsay, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2015.05.001DOI Listing
September 2015

10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.

Eur Respir J 2015 Jul 16;46(1):280-2. Epub 2015 Apr 16.

Drug Development Dept, Gustave Roussy Cancer Campus, University Paris-Sud, Villejuif, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/09031936.00017315DOI Listing
July 2015

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.

J Thorac Oncol 2015 Jun;10(6):e44-5

Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000501DOI Listing
June 2015

Lung cancer in never-smokers.

Eur Respir J 2015 May;45(5):1214-7

Dept of Medical Oncology, Gustave Roussy, Villejuif, France Paris-Sud University, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/09031936.00046915DOI Listing
May 2015

GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.

Eur J Endocrinol 2015 Apr 10;172(4):R151-66. Epub 2014 Nov 10.

Interventional RadiologyMedical OncologyNuclear Medicine and Endocrine OncologyOncology SurgeryEndocrinologyInstitut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, FranceUniversité Paris-SudLe Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EJE-14-0630DOI Listing
April 2015

[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].

Bull Cancer 2015 Apr 25;102(4):381-9. Epub 2015 Mar 25.

Institut Gustave-Roussy, département d'innovation thérapeutique et d'essais précoces, 94805 Villejuif, France; Institut Gustave-Roussy, département de médecine oncologique, 94805 Villejuif, France; Université Paris-Sud, 75011 Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2015.02.016DOI Listing
April 2015

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1689-99

From the Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston (P.A.J.); National Taiwan University and National Taiwan University Hospital (J.C.-H.Y.) and Cheng Kung University Hospital (W.-C.S.) - both in Taipei, Taiwan; Seoul National University Hospital (D.-W.K.), Samsung Medical Center (M.-J.A.), Asan Medical Center (S.-W.K.), and Yonsei Cancer Center, Yonsei University Health System (J.-H.K.) - all in Seoul, South Korea; Institut Gustave Roussy, Villejuif, France (D.P.); National Cancer Center Hospital, Tokyo (Y.O.); Winship Cancer Institute of Emory University, Atlanta (S.S.R.); Vanderbilt Ingram Cancer Center, Nashville (L.H.); Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC (D.H.); Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.); and AstraZeneca, Macclesfield (P.F., M.C., K.H.B., P.A.D., S.G.), and University of Manchester, Christie Hospital, Manchester (M.R.) - both in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411817DOI Listing
April 2015

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Expert Rev Anticancer Ther 2015 Feb 21;15(2):225-33. Epub 2014 Nov 21.

Department of Respiratory Medicine and Thoracic Oncology, Hôpital Louis Pradel, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/14737140.2014.98
Publisher Site
http://dx.doi.org/10.1586/14737140.2014.986103DOI Listing
February 2015

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

Bull Cancer 2014 Sep;101(9):823-31

AP-HP Marseille, Université Aix-Marseille, Service d'oncologie multidisciplinaire & innovations thérapeutiques, 13015 Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2014.1976DOI Listing
September 2014

Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials.

Onkologie 2013 13;36(6):357-62. Epub 2013 May 13.

SITEP (Service des Innovations Therapeutiques Precoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000351257DOI Listing
January 2014

Identification of driver mutations in lung cancer: first step in personalized cancer.

Authors:
David Planchard

Target Oncol 2013 Mar 1;8(1):3-14. Epub 2013 Feb 1.

Department of Medical Oncology (Thoracic Unit), Institut-Gustave-Roussy, 114 rue Edouard Vaillant, 94805, Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11523-013-0263
Web Search
http://link.springer.com/10.1007/s11523-013-0263-z
Publisher Site
http://dx.doi.org/10.1007/s11523-013-0263-zDOI Listing
March 2013

Intervention in gastro-enteropancreatic neuroendocrine tumours.

Best Pract Res Clin Gastroenterol 2012 Dec;26(6):855-65

Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2013.01.008DOI Listing
December 2012

p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients.

Cancer 2012 Oct 13;118(20):5015-25. Epub 2012 Mar 13.

French Institute of Health and Medical Research U981 Thoracic Unit, Gustave Roussy Institute, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27510DOI Listing
October 2012

Small cell lung cancer: new clinical recommendations and current status of biomarker assessment.

Eur J Cancer 2011 Sep;47 Suppl 3:S272-83

Medical Oncology Department, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049117017
Publisher Site
http://dx.doi.org/10.1016/S0959-8049(11)70173-3DOI Listing
September 2011

Bevacizumab in non-small-cell lung cancer: a review.

Authors:
David Planchard

Expert Rev Anticancer Ther 2011 Aug;11(8):1163-79

Département de Médecine, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/era.11.80
Publisher Site
http://dx.doi.org/10.1586/era.11.80DOI Listing
August 2011

[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment].

Presse Med 2011 Apr 21;40(4 Pt 1):371-8. Epub 2011 Mar 21.

Institut Gustave-Roussy, département de médecine, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2011.02.001DOI Listing
April 2011

[DNA repair pathways and non-small cell lung cancer: clinical perspectives].

Bull Cancer 2011 Mar;98(3):305-22

Institut Gustave-Roussy, université Paris-Sud, Inserm U, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1327DOI Listing
March 2011